Table 3 Distribution of study subjects according to principal related medications

16.0

4.3

1.18 (0.97–1.44)

0.102

52.4

19.6

1.47 (1.27–1.70)

<0.001

12.8

5.3

0.99 (0.81–1.22)

0.949

6.4

3.2

0.97 (0.73–1.29)

0.851

0.6

0.2

0.81 (0.30–2.17)

0.673

74.7

39.3

1.86 (1.59–2.17)

<0.001

25.3

6.5

2.20 (1.88–2.59)

<0.001

22.2

1.8

5.46 (4.56–6.53)

<0.001

0.0

0.0

0.00 (0.00–0.00)

0.999

36.3

9.8

2.08 (1.79–2.41)

<0.001

16.3

2.2

2.90 (2.37–3.55)

<0.001

0.1

0.1

0.20 (0.03–1.51)

0.118

30.5

3.8

3.56 (3.02–4.21)

<0.001

3.5

0.9

1.05 (0.71–1.57)

0.802

2.5

0.5

1.58 (1.00–2.49)

0.048

63.5

33.3

1.54 (1.33–1.78)

<0.001

11.6

4.4

0.94 (0.75–1.16)

0.549

3.7 (2.0)

1.4 (1.5)

1.96 (1.73–2.18)^a

<0.001